ArticleNature biomedical engineering2023
Screening hydrogels for antifibrotic properties by implanting cellularly barcoded alginates in mice and a non-human primate.
Article in Nature biomedical engineering, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 52 citations in OpenAlex.
- Once yearly cell-based therapy for sustained and dose-tunable delivery of monoclonal antibodies.Science advances · 2026Article
- Localized immunomodulation with cytokine-producing cells to mitigate foreign body responses in rodents and a nonhuman primate.Science advances · 2026Article
- A modular hydrogel system with independent control of bioadhesion, fibrosis, and stiffness.Science advances · 2026Article
- A Facile and Versatile Technique for Creating Antifibrotic Coatings on Biomedical Implants.bioRxiv : the preprint server for biology · 2026Article
- Artificial intelligence-assisted design and optimization of stimuli-responsive nanocarriers for smart drug delivery.Materials today. Bio · 2026Review
- Delivery of cytokines via encapsulated human astrocytes for neural immunomodulation.Biomaterials · 2026Article
- Molecular Biointerface Characterization for an Implanted Medical Device Using Cryogenic Orbitrap Secondary Ion Mass Spectrometry (Cryo-OrbiSIMS).ACS applied materials & interfaces · 2026Article
- Immunomodulatory Biomaterials for Bone and Soft Tissue Chronic Inflammation Diseases.Small science · 2025Review
- Zwitterionic hydrogel designs for conducting polymers enable bioelectronics with suppressed foreign body responses.bioRxiv : the preprint server for biology · 2025Article
- An injectable hydrogel containingRSC advances · 2025Article
- Immunomodulatory bioadhesive technologies.Biomaterials · 2025Review
- Immunocompatible Elastomer With Enhanced Fibrous Capsule-Resistance and Elasticity by Water-Induced Surface Phase Reconfiguration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- A continuously oxygenated macroencapsulation system enables high-density packing and delivery of insulin-secreting cells.Nature communications · 2025Article
- Cell Therapy for T1D Beyond BLA: Gearing Up Toward Clinical Practice.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Review
- Bioprinted platform for parallelized screening of engineered microtissues in vivo.Cell stem cell · 2025Article
- Delivering living medicines with biomaterials.Nature reviews. Materials · 2025Article
- Antifouling Immunomodulatory Copolymer Architectures That Inhibit the Fibrosis of Implants.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- The future of islet transplantation beyond the BLA approval: challenges and opportunities.Frontiers in transplantation · 2025Review
- Immunocompatible elastomer with increased resistance to the foreign body response.Nature communications · 2024Article
- Emerging approaches for the development of artificial islets.Smart medicine · 2024Review
Corrections and comments
- Commented on by
Authors and funding
20 authors at 7 institutions in 2 countries.
Funding
Abstract
Screening implantable biomaterials for antifibrotic properties is constrained by the need for in vivo testing. Here we show that the throughput of in vivo screening can be increased by cellularly barcoding a chemically modified combinatorial library of hydrogel formulations. The method involves the implantation of a mixture of alginate formulations, each barcoded with human umbilical vein endothelial cells from different donors, and the association of the identity and performance of each formulation by genotyping single nucleotide polymorphisms of the cells via next-generation sequencing. We used the method to screen 20 alginate formulations in a single mouse and 100 alginate formulations in a single non-human primate, and identified three lead hydrogel formulations with antifibrotic properties. Encapsulating human islets with one of the formulations led to long-term glycaemic control in a mouse model of diabetes, and coating medical-grade catheters with the other two formulations prevented fibrotic overgrowth. High-throughput screening of barcoded biomaterials in vivo may help identify formulations that enhance the long-term performance of medical devices and of biomaterial-encapsulated therapeutic cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.